The AlcoHAWK Elite Slim was introduced in 2006 at the Consumer Electronics Show to the AlcoHAWK Series line of digital breath alcohol testers. Operating on a single button, simply blow into the folding mouthpiece for an accurate BAC reading in seconds. The AlcoHAWK Slim also includes removable mouthpiece covers that allow you to test multiple individuals in a sanitary fashion. The sleek design also makes the AlcoHAWK Slim very compact and easy to carry for personal use. It is the ideal solution for someone looking for a portable tester with professional quality with a consumer design and feel. Meets DOT/NHTSA Model Specifications for Breath Alcohol Screeners. Has obtained Premarket Clearance.
The FC10 Portable Breath Alcohol Tester is the true workhorse of breathalyzers. Widely used by Law Enforcement and Corrections the FC10 combines high precision, ease of use and ruggedness with affordability. The Lifeloc FC10 includes direct BAC testing and passive alcohol screening in one instrument. Passive testing does not require a mouthpiece and is perfect for rapid "zero tolerance" alcohol screening of subjects and "sniffing" of open containers. Known for its long life and fast recovery times, the FC10 is likely the only breath alcohol tester you will ever need.
For ease of use and operator safety the FC10 provides audible and graphical breath flow and alcohol content indicators to signal important test situations such as insufficient breath, reverse breath flow, possible uncooperative subjects and a pre-indication of low, medium or high BAC subject levels. Actual BAC results are displayed on the large easy to read display.
The Precision Hand Held Reader Drug Test Cassette is a fast visual, competitive panel immunoassay that can be used for the qualitative detection of drug metabolites at specific cutoff levels in human Saliva
Up to 99% Accurate
Immediate Results
Shelf-life up to 18 months
Collect the specimen with collector
Read the results immediately
Ideal for low-volume donations
These drug tests are intended for workplace testing & forensic use ONLY (not FDA cleared or CLIA waived).
The Discover Drug Test Cassette is a fast visual, competitive panel immunoassay that can be used for the qualitative detection of drug metabolites at specific cutoff levels in human Saliva
Up to 99% Accurate
Immediate Results
Shelf-life up to 18 months
Collect the specimen with collector
Add 3 drops to the well
Read the results immediately
Ideal for low-volume donations
These drug tests are intended for workplace testing & forensic use ONLY (not FDA cleared or CLIA waived).
The Discover Drug Test Cassette is a fast visual, competitive panel immunoassay that can be used for the qualitative detection of drug metabolites at specific cutoff levels in human saliva.
Up to 99% Accurate
Immediate Results
Shelf-life up to 18 months
Collect the specimen with collector
Add 3 drops to the well
Read the results immediately
Ideal for low-volume donations
These are screening devices only and although very accurate if you get a positive we recommend a certified lab for LC-MS/MS Confirmation.
These drug tests are intended for workplace testing & forensic use ONLY (not FDA cleared or CLIA waived).
170 Medical Healthcare Suppliers
Short on time? Let Medical Healthcare sellers contact you.
BinaxNOW COVID-19 Ag Card
For Rapid Detection of SARS-CoV-2 | FDA EUA | IVD Use | RX Only
The BinaxNOW COVID-19 Ag Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nasal (nares) swabs during the acute phase of infection.
Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status.
Negative results should be treated as presumptive, do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions.
The BinaxNOW COVID-19 Ag Card is intended for use by medical professionals or trained operators who are proficient in performing rapid lateral flow tests. BinaxNOW COVID-19 Ag Card is only for use under the Food and Drug Administration's EUA.
Kit Details
Test Card: 40 cards with test strips
Extraction Reagent: bottle containing 7.5 mL of extraction reagent
Nasal swabs: 40 sterile, single use specimen sampling swabs
Positive Control Swab: 1 each â??individually wrapped for single use
Negative Control Swab: 1 each â??individually wrapped for single use
Documentation: Product Insert, Procedure Card
Performance Data
Our best selling fully automatic upper arm digital home blood pressure monitor.
The 6021N features:
Measures systolic, diastolic pressure, and pulse
British Hypertension Society (BHS) AA rating ensures unrivaled accuracy
Smart Logicâ?¢ Technology determines ideal inflation level
Irregular Heartbeat detector
Automatic inflation and deflation control
Recalls last 99 readings with date and time stamp for two users
Self-adjusting extended range latex-free D-Bar cuff fits arm ranges from 8.7 to 16.5 (22 cm to 42 cm)
Auto-off
Not made with natural rubber latex
4 AA batteries included
Deluxe Storage case
Optional AC adapter (sold separately)
Meets or exceeds EN 1060-1, and EN 1060-3
5 Year Warranty
Use of this test with all authorized specimen types is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.
This test is also authorized for use with fingerstick whole blood specimens only at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The CLIA Waived COVID-19 IgG/IgM Rapid Test Device is an in vitro immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only.
Indication:
Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories.
About Test Device
EUA Authorized
CE Mark
Test does NOT give positive or negative result for COVID-19 virus. This is an antibody test, it only indicates past or recent infection.
Read Results in 15 Minutes
9 Month Expiration from Date of Manufacture
Contents
The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
Lateral flow assay
Detect SARS-CoV-2 nucleocapsid protein antigen
Rapid results within 10-15 minutes
Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
For use under the Emergency Use Authorization (EUA) only
For in vitro diagnostic use only
For prescription use only
For use with direct anterior nasal and nasopharyngeal swab specimens
Clinical Performance
93.75% PPAa and 99.32% NPAb when used with nasopharyngeal swab
87.18% PPAa and 100% NPAb when used with anterior nasal swab
The COVID-19 IgG/IgM Rapid Test Device is an in vitro Immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only.
Indication:
Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
About Test Device
Gives Positive or Negative Result for COVID-19 IgM/IgG antibodies
Read Results in 15 Minutes
Contents of each box
